Compare KTCC & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTCC | CALC |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 7.6M |
| IPO Year | 1995 | 2020 |
| Metric | KTCC | CALC |
|---|---|---|
| Price | $1.32 | $1.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $38.00 |
| AVG Volume (30 Days) | 29.9K | ★ 62.6K |
| Earning Date | 11-03-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,871,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.25 | $0.44 |
| 52 Week High | $4.42 | $72.00 |
| Indicator | KTCC | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 20.16 | 41.27 |
| Support Level | $1.25 | $1.08 |
| Resistance Level | $2.28 | $1.84 |
| Average True Range (ATR) | 0.17 | 0.22 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 8.59 | 8.81 |
Key Tronic Corp is a contract manufacturer offering value-added design and manufacturing services from its facilities in the United States, Mexico, and Vietnam with procurement support from its facility in China. The company provides its customers full engineering services, materials management, manufacturing facilities, assembly services, in-house testing, and distribution. Its customers include original equipment manufacturers. Its capabilities are Printed Circuit Board Assembly, Injection Molding and Tooling, Metal Fabricating and Finishing, Full Product Assembly, Design and Engineering Support, and Logistics and Repair Center, and Supply Chain Management. It operates and internally manages a single operating segment, Electronics Manufacturing Services.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.